Otsuka Holdings Co., Ltd. (OTSKF)
USD 57.15
(0.0%)
USD 57.15
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 121.61 Billion JPY | -9.18% |
| 2022 | 133.9 Billion JPY | 6.73% |
| 2021 | 125.46 Billion JPY | -15.31% |
| 2020 | 148.13 Billion JPY | 16.5% |
| 2019 | 127.15 Billion JPY | 54.14% |
| 2018 | 82.49 Billion JPY | -26.67% |
| 2017 | 112.49 Billion JPY | 21.53% |
| 2016 | 92.56 Billion JPY | 10.08% |
| 2015 | 84.08 Billion JPY | 0.0% |
| 2014 | - JPY | -100.0% |
| 2013 | 122.42 Billion JPY | 32.82% |
| 2012 | 92.17 Billion JPY | 13.79% |
| 2011 | 81 Billion JPY | 20.1% |
| 2010 | 67.44 Billion JPY | 43.24% |
| 2009 | 47.08 Billion JPY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 30.41 Billion JPY | -60.69% |
| 2024 Q1 | 77.37 Billion JPY | 292.97% |
| 2023 Q2 | 41.16 Billion JPY | -32.99% |
| 2023 FY | 121.61 Billion JPY | -9.18% |
| 2023 Q3 | 59.11 Billion JPY | 43.62% |
| 2023 Q4 | -40.09 Billion JPY | -167.83% |
| 2023 Q1 | 61.43 Billion JPY | 167.21% |
| 2022 Q4 | 22.98 Billion JPY | -44.29% |
| 2022 Q3 | 41.26 Billion JPY | -11.3% |
| 2022 Q2 | 46.52 Billion JPY | 100.09% |
| 2022 Q1 | 23.25 Billion JPY | 2062.03% |
| 2022 FY | 133.9 Billion JPY | 6.73% |
| 2021 Q1 | 44.68 Billion JPY | 119.34% |
| 2021 Q4 | -1.18 Billion JPY | -103.36% |
| 2021 FY | 125.46 Billion JPY | -15.31% |
| 2021 Q2 | 46.72 Billion JPY | 4.57% |
| 2021 Q3 | 35.24 Billion JPY | -24.58% |
| 2020 Q2 | 49.1 Billion JPY | 30.2% |
| 2020 Q3 | 40.95 Billion JPY | -16.59% |
| 2020 Q4 | 20.37 Billion JPY | -50.26% |
| 2020 Q1 | 37.71 Billion JPY | 141.24% |
| 2020 FY | 148.13 Billion JPY | 16.5% |
| 2019 Q3 | 43.75 Billion JPY | -9.99% |
| 2019 FY | 127.15 Billion JPY | 54.14% |
| 2019 Q1 | 19.15 Billion JPY | 297.84% |
| 2019 Q2 | 48.61 Billion JPY | 153.82% |
| 2019 Q4 | 15.63 Billion JPY | -64.27% |
| 2018 Q3 | 13.8 Billion JPY | -66.81% |
| 2018 Q1 | 22.72 Billion JPY | -42.36% |
| 2018 FY | 82.49 Billion JPY | -26.67% |
| 2018 Q4 | 4.81 Billion JPY | -65.12% |
| 2018 Q2 | 41.57 Billion JPY | 82.94% |
| 2017 Q2 | 21.41 Billion JPY | 1.91% |
| 2017 FY | 112.49 Billion JPY | 21.53% |
| 2017 Q4 | 39.42 Billion JPY | 28.69% |
| 2017 Q3 | 30.63 Billion JPY | 43.07% |
| 2017 Q1 | 21.01 Billion JPY | 969.31% |
| 2016 Q3 | 58.02 Billion JPY | 109.05% |
| 2016 FY | 92.56 Billion JPY | 10.08% |
| 2016 Q1 | 21.85 Billion JPY | 214.78% |
| 2016 Q2 | 27.75 Billion JPY | 26.98% |
| 2016 Q4 | 1.96 Billion JPY | -96.61% |
| 2015 Q4 | -19.04 Billion JPY | -156.58% |
| 2015 FY | 84.08 Billion JPY | 0.0% |
| 2015 Q3 | 33.65 Billion JPY | -5.23% |
| 2015 Q2 | 35.51 Billion JPY | 4.58% |
| 2015 Q1 | 33.96 Billion JPY | 0.0% |
| 2014 Q2 | 45.24 Billion JPY | 454.62% |
| 2014 FY | - JPY | -100.0% |
| 2014 Q3 | 54.25 Billion JPY | 19.92% |
| 2014 Q1 | 8.15 Billion JPY | -85.38% |
| 2013 Q1 | 31.23 Billion JPY | 9.42% |
| 2013 Q2 | 39.7 Billion JPY | 27.12% |
| 2013 Q3 | 47.31 Billion JPY | 19.17% |
| 2013 FY | 122.42 Billion JPY | 32.82% |
| 2013 Q4 | 55.81 Billion JPY | 17.97% |
| 2012 FY | 92.17 Billion JPY | 13.79% |
| 2012 Q3 | 30.72 Billion JPY | -3.77% |
| 2012 Q4 | 28.54 Billion JPY | -7.1% |
| 2012 Q1 | 3.54 Billion JPY | -88.74% |
| 2012 Q2 | 31.92 Billion JPY | 801.95% |
| 2011 Q4 | 31.43 Billion JPY | 20.68% |
| 2011 Q1 | 11.59 Billion JPY | -28.55% |
| 2011 Q2 | 31.15 Billion JPY | 168.79% |
| 2011 FY | 81 Billion JPY | 20.1% |
| 2011 Q3 | 26.04 Billion JPY | -16.4% |
| 2010 Q1 | 1.93 Billion JPY | -90.41% |
| 2010 FY | 67.44 Billion JPY | 43.24% |
| 2010 Q3 | 31.48 Billion JPY | 48.62% |
| 2010 Q2 | 21.18 Billion JPY | 992.57% |
| 2010 Q4 | 16.22 Billion JPY | -48.48% |
| 2009 Q3 | 25.55 Billion JPY | 29.53% |
| 2009 FY | 47.08 Billion JPY | 0.0% |
| 2009 Q2 | 19.73 Billion JPY | 0.0% |
| 2009 Q4 | 20.21 Billion JPY | -20.91% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AstraZeneca PLC | 5.95 Billion USD | -1942.25% |
| Bristol-Myers Squibb Company PFD CONV 2 | 8.02 Billion USD | -1415.464% |
| CSPC Pharmaceutical Group Limited | 830.91 Million USD | -14536.372% |
| Clarus Therapeutics Holdings, Inc. | -56.51 Million USD | 215303.851% |
| Novartis AG | 14.85 Billion USD | -718.963% |
| PT Kalbe Farma Tbk. | 179.7 Million USD | -67575.153% |